Aug 12, 2020
QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma
Jun 21, 2020
Ascentage Pharma Enters Clinical Collaboration to Evaluate the Combination of Bcl-2 and BTK Inhibitors
Jun 19, 2020
FDA approves new Dupixent® (dupilumab) pre-filled pen designed to support more convenient self-administration
Jun 19, 2020
Dupixent® (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Jun 18, 2020
Linnaeus Therapeutics Granted U.S. FDA Fast Track Designation for LNS8801 for the Treatment of Patients with Metastatic or Unresectable Melanoma Who Have Progressed on Anti-PD-1/L1 Therapy
Jun 16, 2020
Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer
Jun 16, 2020
CAR-T Therapy Market Outlook to 2030 by Target Antigen, Application, Region, Country and Company
Jun 13, 2020
Halozyme Announces Findings From Janssen's Phase 3 Andromeda Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® In Light-Chain Amyloidosis Presented At European Hematology Association 25th Annual Congress
Jun 13, 2020
VENCLEXTA®/VENCLYXTO® (venetoclax) Plus Azacitidine Demonstrates Statistically Significant Overall Survival Benefit and Improved Remission Rates in Treatment-Naïve Acute Myeloid Leukemia Patients
Jun 12, 2020
EHA25Virtual: A New Paradigm in Relapsed Refractory Hodgkin Lymphoma
Jun 12, 2020
EHA25Virtual: Advances in Treatment of High Risk Chronic Lymphocytic Leukemia
Jun 10, 2020
AbbVie and Genmab Announce Broad Oncology Collaboration
Jun 10, 2020
F2G's Olorofim Receives Both FDA Orphan Drug Designation for Coccidioidomycosis (Valley Fever) and FDA QIDP Designation for Multiple Fungal Infections
Jun 09, 2020
OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO(TM) and KEYTRUDA® Plus Chemotherapy
Jun 01, 2020
Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
May 29, 2020
Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN® (eribulin mesylate) plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Triple-Negative Breast Cancer at ASCO 2020
May 29, 2020
Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable Clinical Activity and Well-Tolerated Safety Profile of Pralsetinib Across Broad Range of RET Fusion-Positive Tumors
May 27, 2020
Novartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)
May 27, 2020
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease
May 22, 2020
Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal